Skip to main content
SpringerLink
Log in

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

  • Original Articles
  • Cyclophosphamide, Pharmacokinetics, Breast Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Cyclophosphamide pharmacolinetics have been studied in 16 female patients with advanced breast cancer. The group included 7 patients who were >20%, ≤30% over ideal body weight and 5 patients who were >30% over ideal body weight. Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.31 (mean 36.11), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min). There was a significant positive correlation (r=0.624,P=0.010) between body weight and plasma elimination half-life, and a significant negative correlation between body weight and cyclophosphamide clearance when normalized to body surface area (r=0.578,P=0.019) or normalized to ideal body weight (r=0.531,P=0.0345). the apparent volume of distribution did not correlate with body weight. The results show that cyclophosphamide disposition is altered in patients with increased body weight.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abernethy DR, Greeblatt DJ (1982) Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 7: 108

    Google Scholar 

  2. Abernethy DR, Greenblatt DJ (1984) Lidocaine disposition in obesity. Am J Cardiol 53: 1183

    Google Scholar 

  3. Abernethy DR, Greeblatt DJ (1985) Ibuprofen disposition in obesity. Arthritis Rheum 28: 1117

    Google Scholar 

  4. Abernethy DR, Greenblatt DJ (1986) Drug disposition in obese humans, an update. Clin Pharmacokinet 11: 199

    Google Scholar 

  5. Abernethy DR, Greenblatt DJ, Divoll M, Hermatz JS, Shader RI (1981) Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 217: 681

    Google Scholar 

  6. Abernethy DR, Greenblatt DJ, Smith TW (1981) Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 102: 740

    Google Scholar 

  7. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B (1982) Pharmacokinetics of drugs in obesity. Clin Pharmacol Ther 31: 783

    Google Scholar 

  8. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI (1983) Enhanced glucuronide conjugation of drugs in obesity; studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 101: 873

    Google Scholar 

  9. Abernethy DR, Todd EL, Schwartz JB (1985) Caffeine disposition in obesity. Br J Clin Pharmacol 20: 61

    Google Scholar 

  10. Adler M, Schaffner F (1979) Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67: 811

    Google Scholar 

  11. Bagley CM, Bostick FW, DeVita VT (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226

    Google Scholar 

  12. Bauer LA, Wareing-Tran C, Edwards WAD, Raisys V, Ferrer L, et al (1985) Cimetidine clearance in the obese. Clin Pharmacol Ther 37: 424

    Google Scholar 

  13. Benedek IH, Fiske WD, Griffen WO, Bell RM, Blouin RA, et al (1983) Serum alpha-1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 16: 751

    Google Scholar 

  14. Braumwell V, Calvert RT, Edwards G, Scarffe H, Crowther D (1979) The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 3: 253

    Google Scholar 

  15. Bray GA (1979) Obesity. Disease-a-month 26 (October): 7

    Google Scholar 

  16. Brouwer KLR, Kostenbauder HB, McNamara PJ, Blouin RA (1984) Phenobarbital in the genetically obese Zucker rat: II. In vivo and in vitro assessments of microsomal enzyme inducation. J Pharmacol Exp Ther 231: 654

    Google Scholar 

  17. Christoff PD, Conti DR, Naylor C, Jusko WJ (1983) Procainamide disposition in obesity. Drug Intell Clin Pharm 17: 516

    Google Scholar 

  18. De Divitiis O, Fazio S, Pettito M, Maddalena G, Contalde F, et al (1981) Obesity and cardiac function. Circulation 64: 477

    Google Scholar 

  19. D'Incalci MD, Bolis G, Mangioni C, Morosa L, Garattini S (1978) Variable absorption of hexamethylmelamine in man. Cancer Treat Rep 62: 2117

    Google Scholar 

  20. D'Incalci MD, Beggiolin G, Sessa C, Mangioni C (1981) Influence of ascites on the pharmacokinetics of hexamethylmelamine andN-demethylated metabolites in ovarian cancer patients. Eur J Clin Oncol 12: 13331

    Google Scholar 

  21. Dionne RE, Bauer LA, Gibson GA, Griffen WO, Blouin RA (1981) Estimating creatinine clearance in morbidly obese patients. Am J Hosp Pharm 38: 841

    Google Scholar 

  22. Dorsey JL, Smith JT (1981) Comparison of hepatic cytochrome P-450 levels of obese mice and nonobese mice. Nutr Rep Int 24: 777

    Google Scholar 

  23. Forbes GB, Welle SL (1983) Lean body mass in obesity. Int J Obesity 7: 99

    Google Scholar 

  24. Gal P, Jusko WJ, Yurchak AM, Franklin BA (1978) Theophylline disposition in obesity. Clin Pharmacol Ther 23: 438

    Google Scholar 

  25. Grochow LB, Colvin M (1979) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 4: 380

    Google Scholar 

  26. Harris RN, Basseches PJ, Appel PL, Durski AM, Powis G (1984) Carbon tetrachloride induced increase in the antitumor activity of cyclophosphamide in mice: A pharmacokinetic study. Cancer Chemother Pharmacol 12: 167

    Google Scholar 

  27. Juma F, Ogada T (1983) Pharmacokinetics of cyclophosphamide in Kenyan Africans. Br J Clin Pharmacol 16: 61

    Google Scholar 

  28. Juma FD, Rogers HJ, Trounce JR (1980) The pharmacokinetics of cyclophosphamide phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 10: 327

    Google Scholar 

  29. Juma FD, Rogers HJ, Trounce JR (1981) Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19: 443

    Google Scholar 

  30. Kirschner MA, Schneider G, Ertel NH, Worton E (1982) Obesity, androgens, estrogens and cancer risk. Cancer Res 42 [Suppl]: 3281s

  31. Metzler CM, Elfring G, McEwen B (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562

    Google Scholar 

  32. Milsap RL, Plaisance IL, Jusko WJ (1984) Prednisolone disposition in obese man. Clin Pharmacol Ther 36: 824

    Google Scholar 

  33. Ottolenghi L, Morasca L, Marsoni S, Piazza E, Soresi E, Libretti A, Garattini S (1980) Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens. Biomedicine 32: 123

    Google Scholar 

  34. Powis G (1983) Effects of diseases states on pharmacokinetics of anticancer drugs. In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, Amsterdam, p 363

    Google Scholar 

  35. Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14: 177

    Google Scholar 

  36. Powis G, Reece PA, Ingle JM, Ahmann DL (1986) Cyclophosphamide pharmacokinetics in obese cancer patients. Acta Pharmacol Toxicol 59 [Suppl V]: 296

    Google Scholar 

  37. Ritschel WA, Bykadi G, Norman EJ, Cluxton RJ, Denton D (1981) Salivary elimination of cyclophosphamide in man. J Clin Pharmacol 21: 461

    Google Scholar 

  38. Rohrbaugh TM, Danish M, Ragni MC, Yaffe SJ (1982) The effect of obesity on apparent volume of distribution of theophylline. Pediatr Pharmacol (New York) 2: 75

    Google Scholar 

  39. Sketris I, Lesar T, Zaske DE, Cipolle RJ (1982) Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 21: 288

    Google Scholar 

  40. Sladek NE (1987) Oxazaphosphorines. In: Powis G, Prough R (eds) Metabolism and actions of anticancer drugs. Taylor and Francis, London, p 48

    Google Scholar 

  41. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W (1980) Plasma half-life and urinary excretion of cyclophosphamide in pediatric patients. Cancer Treat Rep 64: 1061

    Google Scholar 

  42. Wagner JG (1976) Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4: 443

    Google Scholar 

Download references

Author information

Author notes

  1. Phillip Reece

    Present address: Department of Clinical Pharmacology, Queen Elizabeth Hospital, 5011, Woodville, South Australia, Australia

Authors and Affiliations

  1. Department of Pharmacology, Mayo Clinic & Foundation, 200 First Street, S. W., 55905, Rochester, MN, USA

    Garth Powis

  2. Department of Oncology, Mayo Clinic & Foundation, 55905, Rochester, Minnesota, USA

    Phillip Reece, David L. Ahmann & James N. Ingle

Authors
  1. Garth Powis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phillip Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David L. Ahmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James N. Ingle
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Powis, G., Reece, P., Ahmann, D.L. et al. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother. Pharmacol. 20, 219–222 (1987). https://doi.org/10.1007/BF00570489

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00570489

Keywords

Search

Navigation